GPS Wealth Strategies Group LLC Has $152,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

GPS Wealth Strategies Group LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 275 shares of the medical research company’s stock after buying an additional 31 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Thermo Fisher Scientific were worth $152,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. International Assets Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 17.0% during the fourth quarter. International Assets Investment Management LLC now owns 1,902 shares of the medical research company’s stock worth $1,010,000 after purchasing an additional 276 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its position in Thermo Fisher Scientific by 19.8% during the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,108 shares of the medical research company’s stock worth $1,119,000 after purchasing an additional 348 shares during the last quarter. London & Capital Asset Management Ltd grew its position in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. London & Capital Asset Management Ltd now owns 69,708 shares of the medical research company’s stock valued at $37,000,000 after buying an additional 4,506 shares during the last quarter. Ballast Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 57.3% in the fourth quarter. Ballast Advisors LLC now owns 1,531 shares of the medical research company’s stock valued at $813,000 after buying an additional 558 shares during the period. Finally, Sentry Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 32.0% during the fourth quarter. Sentry Investment Management LLC now owns 2,959 shares of the medical research company’s stock worth $1,571,000 after acquiring an additional 718 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The disclosure for this sale can be found here. Insiders have sold 33,084 shares of company stock worth $19,767,092 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $0.09 during trading hours on Thursday, reaching $602.01. The company had a trading volume of 304,477 shares, compared to its average volume of 1,544,905. The business has a fifty day simple moving average of $569.93 and a 200 day simple moving average of $571.23. The firm has a market cap of $229.80 billion, a PE ratio of 38.66, a price-to-earnings-growth ratio of 2.77 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $5.15 earnings per share. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on TMO shares. HSBC raised their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Raymond James boosted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.